SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Daha Mohamed R.)
 

Search: WFRF:(Daha Mohamed R.) > Zinc supplementatio...

Zinc supplementation inhibits complement activation in age-related macular degeneration.

Smailhodzic, Dzenita (author)
van Asten, Freekje (author)
Blom, Anna (author)
Lund University,Lunds universitet,Proteinkemi, Malmö,Forskargrupper vid Lunds universitet,Protein Chemistry, Malmö,Lund University Research Groups
show more...
Mohlin, Frida (author)
Lund University,Lunds universitet,Proteinkemi, Malmö,Forskargrupper vid Lunds universitet,Protein Chemistry, Malmö,Lund University Research Groups
den Hollander, Anneke I (author)
van de Ven, Johannes P H (author)
van Huet, Ramon A C (author)
Groenewoud, Joannes M M (author)
Tian, Yuan (author)
Berendschot, Tos T J M (author)
Lechanteur, Yara T E (author)
Fauser, Sascha (author)
de Bruijn, Chris (author)
Daha, Mohamed R (author)
van der Wilt, Gert Jan (author)
Hoyng, Carel B (author)
Klevering, B Jeroen (author)
show less...
 (creator_code:org_t)
2014-11-13
2014
English.
In: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 9:11
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. AMD is a multifactorial disorder but complement-mediated inflammation at the level of the retina plays a pivotal role. Oral zinc supplementation can reduce the progression of AMD but the precise mechanism of this protective effect is as yet unclear. We investigated whether zinc supplementation directly affects the degree of complement activation in AMD and whether there is a relation between serum complement catabolism during zinc administration and the complement factor H (CFH) gene or the Age-Related Maculopathy susceptibility 2 (ARMS2) genotype. In this open-label clinical study, 72 randomly selected AMD patients in various stages of AMD received a daily supplement of 50 mg zinc sulphate and 1 mg cupric sulphate for three months. Serum complement catabolism-defined as the C3d/C3 ratio-was measured at baseline, throughout the three months of supplementation and after discontinuation of zinc administration. Additionally, downstream inhibition of complement catabolism was evaluated by measurement of anaphylatoxin C5a. Furthermore, we investigated the effect of zinc on complement activation in vitro. AMD patients with high levels of complement catabolism at baseline exhibited a steeper decline in serum complement activation (p<0.001) during the three month zinc supplementation period compared to patients with low complement levels. There was no significant association of change in complement catabolism and CFH and ARMS2 genotype. In vitro zinc sulphate directly inhibits complement catabolism in hemolytic assays and membrane attack complex (MAC) deposition on RPE cells. This study provides evidence that daily administration of 50 mg zinc sulphate can inhibit complement catabolism in AMD patients with increased complement activation. This could explain part of the mechanism by which zinc slows AMD progression.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Andra medicinska och farmaceutiska grundvetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Other Basic Medicine (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

  • PLoS ONE (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view